Menu
1-702-720-6310 info@microcapspecualtors.com

J&J to spin off Actelion R&D unit into new biotech in major M&A deal – FierceBiotech


FierceBiotech

J&J to spin off Actelion R&D unit into new biotech in major M&A deal
FierceBiotech
Johnson & Johnson has always been partial to a new biotech and under its buyout of Actelion announced early this morning, it’s creating another by spinning off the Swiss company’s research ops. As part of the deal, worth $280 a share or $30 billion
Johnson & Johnson to Buy Swiss Biotech Company Actelion for $30BFox Business
Johnson and Johnson to Acquire Swiss Biotech Firm for $30 Billion (JNJ)Investopedia
J&J to acquire Swiss biotech for $30BNJBIZ
Financial Times –International Business Times, India Edition –Reuters –Johnson & Johnson
all 123 news articles »

Search